Voya Investment Management LLC Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Voya Investment Management LLC significantly increased its stake in Jazz Pharmaceuticals by purchasing an additional 22,628 shares, bringing their total to 56,349 shares worth approximately $6.99 million.
• The company's stock performance indicates volatility with a 52-week low of $95.49 and a high of $148.06, with shares recently opening at $129.54.
• Jazz Pharmaceuticals reported a disappointing EPS of ($8.25) for the last quarter, missing analysts' expectations despite a revenue of $1.05 billion, which met consensus estimates.

Voya Investment Management LLC increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 67.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 56,349 shares of the specialty pharmaceutical company's stock after purchasing an additional 22,628 shares during the quarter. Voya Investment Management LLC owned approximately 0.09% of Jazz Pharmaceuticals worth $6,996,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Jazz Pharmaceuticals by 9.4% during the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after purchasing an additional 91 shares during the period. Kendall Capital Management grew its holdings in Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after buying an additional 95 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Jazz Pharmaceuticals by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after buying an additional 100 shares during the period. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 1.3% in the first quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock worth $1,046,000 after buying an additional 110 shares in the last quarter. Finally, Cardinal Capital Management lifted its holdings in shares of Jazz Pharmaceuticals by 0.9% in the first quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company's stock worth $1,645,000 after buying an additional 114 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on JAZZ shares. The Goldman Sachs Group boosted their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Morgan Stanley boosted their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $178.67.

Jazz Pharmaceuticals Trading Down 2.2%

Jazz Pharmaceuticals stock traded down $2.89 during mid-day trading on Friday, reaching $128.30. 1,488,638 shares of the company traded hands, compared to its average volume of 681,709. The firm's 50 day moving average price is $120.39 and its 200 day moving average price is $116.09. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm has a market capitalization of $7.78 billion, a price-to-earnings ratio of -19.06, a P/E/G ratio of 7.96 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter in the prior year, the firm earned $5.30 EPS. Jazz Pharmaceuticals's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.